Metformin for Antipsychotic-Related Metabolic Syndrome in Children： Fact or Fiction？  

作　　者：Ahmed Naguy Dalai EI-Sori 

机构地区：[1]AI-Manara CAP Centre, Kuwait Centre for Mental Health, Shuwaikh, State of Kuwait [2]Paediatrics Department, Cleveland Clinic Children's, Cleveland, Ohio, USA

出　　处：《Chinese Medical Journal》2018年第12期1490-1491,共2页中华医学杂志（英文版）

摘　　要：Use of atypical antipsychotics （AAPs） in child/adolescent psychiatry （CAP） population is rife to address a wide array of indications. Apart from the Food and Drug Administration approval in schizophrenia, bipolar mood disorders, irritability in autism spectrum disorder, and Tourette＇s syndrome, AAPs are commonly prescribed off-label for aggression in intellectual disability or attention-deficit/hyperactivity disorder, augmentation in depression and obsessive-compulsive disorder.Use of atypical antipsychotics （AAPs） in child/adolescent psychiatry （CAP） population is rife to address a wide array of indications. Apart from the Food and Drug Administration approval in schizophrenia, bipolar mood disorders, irritability in autism spectrum disorder, and Tourette＇s syndrome, AAPs are commonly prescribed off-label for aggression in intellectual disability or attention-deficit/hyperactivity disorder, augmentation in depression and obsessive-compulsive disorder.

分 类 号：R749.94[医药卫生—神经病学与精神病学]